Live Breaking News & Updates on Enterome biosc

Stay informed with the latest breaking news from Enterome biosc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Enterome biosc and stay connected to the pulse of your community

Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma

/PRNewswire/ -- Enterome, a clinical stage company developing first-in-class immunomodulatory drugs based on its gut bacterial Mimicry drug discovery platform,...

United-states , Paris , France-general- , France , Switzerland , Guillaume-bayre , David-reardon , Prnewswire-enterome , Sylvie-berrebi-mark , Head-of-external-communications , Esmo-io-annual-congress , Health-science

Enterome presents two posters on Phase 2 data of its lead immunotherapy, EO2401, in recurrent glioblastoma (ROSALIE study) at ESMO IO 2022

/PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its gut bacterial Mimicry drug...

Germany , Geneva , Genè , Switzerland , Heidelberg , Baden-wüberg , Paris , France-general- , France , German , Guillaume-bayre , Sylvie-berrebi-mark

Enterome announces presentation of data from ongoing Phase 1/2 trial of its peptide-based immunotherapy EO2401 in recurrent glioblastoma (ROSALIE study) at SNO 2022

/PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug...

Florida , United-states , Tampa-bay , Rosalie , Tampa , Paris , France-general- , France , Guillaume-bayre , David-reardon , Sylvie-berrebi-mark , Head-of-external-communications

Enterome's OncoMimics™ peptide-based immunotherapy EO2401 generates and maintains elevated anti-tumor T cell responses for more than 10 months in patients with recurrent glioblastoma

/PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug...

Boston , Massachusetts , United-states , Paris , France-general- , France , Guillaume-bayre , Prnewswire-enterome , Sylvie-berrebi-mark , Jan-fagerberg , Head-of-external-communications , Society-for-immunotherapy-of-cancer

Enterome's OncoMimics peptide-based immunotherapy EO2401 generates and maintains elevated anti-tumor T cell responses for more than 10 months in patients with recurrent glioblastoma

Memory CD8+ T cell response found as early as two weeks after the first administration of EO2401, expanding to up to 5% of circulating specific CD8+ T cells in some patients Immunological

Boston , Massachusetts , United-states , Paris , France-general- , France , Guillaume-bayre , Kostenloser-wertpapierhandel , Prnewswire-enterome , Sylvie-berrebi-mark , Jan-fagerberg , Head-of-external-communications

Enterome to present updated safety, immunogenicity and efficacy data from its Phase 1/2 trial of EO2401 in recurrent glioblastoma (ROSALIE study) at SITC 2022

/PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug...

Boston , Massachusetts , United-states , Dana-farber-cancer-institute , Paris , France-general- , France , Guillaume-bayre , David-reardon , Sylvie-berrebi-mark , Head-of-external-communications , Society-for-immunotherapy-of-cancer

Enterome's Management Attending Upcoming Meetings

PARIS, Oct. 11, 2022 /PRNewswire/ -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for cancer and inflammatory diseases based on its unique Mimicry platform

New-york , United-states , Boston , Massachusetts , Paris , France-general- , France , Guillaume-bayre , Kostenloser-wertpapierhandel , Anne-dagallier , Prnewswire-enterome , Pierre-belichard

Enterome's innovative OncoMimics™-based immunotherapy EO2401 distinguished with 'Best Clinical Research Award' at EANO Meeting 2022 for promising results in recurrent gliobastoma

/PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug...

Austria , Vienna , Wien , Paris , France-general- , France , Guillaume-bayre , Ahmed-idbaih , Sylvie-berrebi-mark , Head-of-external-communications , Journal-of-the-society-for-neuro , European-association-of-neuro

Enterome's innovative OncoMimics-based immunotherapy EO2401 distinguished with 'Best Clinical Research Award' at EANO Meeting 2022 for promising results in recurrent gliobastoma

PARIS, Sept. 16, 2022 /PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug discovery platform

Austria , Vienna , Wien , Paris , France-general- , France , Guillaume-bayre , Kostenloser-wertpapierhandel , Ahmed-idbaih , Prnewswire-enterome , Sylvie-berrebi-mark , Head-of-external-communications

Enterome presents further efficacy data on its new generation therapeutic cancer vaccine EO2401 at ESMO Congress, demonstrating ability of OncoMimics antigens to generate positive clinical outcome

EO2401 is a first-in-class OncoMimics therapeutic cancer vaccine able to significantly expand existing effector memory CD8+ T cells directed at OncoMimics peptides corresponding to tumor-associated

Paris , France-general- , France , Guillaume-bayre , Kostenloser-wertpapierhandel , Prnewswire-enterome , Pierre-belichard , Sylvie-berrebi-mark , Jan-fagerberg , Head-of-external-communications , Health-science , European-society-for-medical-oncology